Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics

[1] Holland EC(2000)Glioblastoma multiforme: the terminator Proc Natl Acad Sci U S A 97 6242-6244

[2] Johnson DR(2012)Glioblastoma survival in the United States before and during the temozolomide era J Neuro-Oncol 107 359-364

[3] O'Neill BP(2010)Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (lancet Oncol. 2009;10:459-466) Cancer 116 1844-1846

[4] Linz U(2014)MGMT testing--the challenges for biomarker-based glioma treatment Nat Rev Neurol 10 372-385

[5] Wick W(2007)Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine Oncogene 26 186-197

[6] Weller M(2009)O6-methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neuro-Oncology 12 28-36

[7] van den Bent M(2019)Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets J Biomed Sci 26 77-79

[8] Sanson M(2019)The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma Cell Death Dis 10 894-113104

[9] Weiler M(2018)beta-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species Cancer Lett 435 66-3920

[10] von Deimling A(2017)Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models Oncotarget 8 113090-1337

[1] Holland EC(2000)Glioblastoma multiforme: the terminator Proc Natl Acad Sci U S A 97 6242-6244

[2] Johnson DR(2012)Glioblastoma survival in the United States before and during the temozolomide era J Neuro-Oncol 107 359-364

[3] O'Neill BP(2010)Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (lancet Oncol. 2009;10:459-466) Cancer 116 1844-1846

[4] Linz U(2014)MGMT testing--the challenges for biomarker-based glioma treatment Nat Rev Neurol 10 372-385

[5] Wick W(2007)Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine Oncogene 26 186-197

[6] Weller M(2009)O6-methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neuro-Oncology 12 28-36

[7] van den Bent M(2019)Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets J Biomed Sci 26 77-79

[8] Sanson M(2019)The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma Cell Death Dis 10 894-113104

[9] Weiler M(2018)beta-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species Cancer Lett 435 66-3920

[10] von Deimling A(2017)Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models Oncotarget 8 113090-1337